Valuation: CSL Limited

Market Cap 44.53B 38.52B 35.97B 33B 62.07B 4,238B 63.05B 422B 166B 2,124B 167B 164B 7,023B P/E 2026 *
-59.8x
P/E 2027 * 32.8x
Enterprise Value 53.25B 46.06B 43.01B 39.46B 74.21B 5,068B 75.39B 505B 198B 2,540B 200B 196B 8,397B EV / Sales 2026 *
3.46x
EV / Sales 2027 * 3.37x
Free-Float
99.3%
Yield 2026 *
3.07%
Yield 2027 * 3.14%
1 day-0.13%
1 week+3.33%
Current month+7.42%
1 month+6.41%
3 months+6.10%
6 months-26.76%
Current year-23.43%
1 week 121.87
Extreme 121.87
133.35
1 month 113.75
Extreme 113.75
133.35
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
273.45
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap.
23/2/26 Free

Director

263 0.0001%
23/2/26 Free 512 0.0001%
19/2/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%+3.33%-50.97%-50.14% 44.59B
+1.23%+2.52%+39.66%+0.92% 77.1B
-0.84%+0.09%+20.92%+179.15% 49.43B
+2.77%+1.90%-1.84%+27.14% 49.27B
-0.25%+1.35%+61.01%-24.16% 30.48B
+1.26%+0.19%+53.13%+84.49% 24B
+6.37%+5.34%+117.02%-42.93% 21.5B
+4.29%+7.66%-3.26%+189.18% 20.18B
+1.66%-3.70%+65.40%+123.91% 16.29B
-0.30%+2.87%+79.30%+166.12% 16.19B
Average +1.60%+0.79%+38.04%+65.37% 34.9B
Weighted average by Cap. +1.30%+2.49%+27.68%+48.48%

Financials

2026 *2027 *
Net sales 15.38B 13.3B 12.42B 11.4B 21.44B 1,464B 21.78B 146B 57.21B 734B 57.76B 56.49B 2,425B 15.59B 13.48B 12.59B 11.55B 21.73B 1,484B 22.07B 148B 57.99B 744B 58.54B 57.26B 2,458B
Net income -967M -836M -781M -716M -1.35B -92B -1.37B -9.16B -3.6B -46.11B -3.63B -3.55B -152B 1.18B 1.02B 957M 878M 1.65B 113B 1.68B 11.23B 4.41B 56.5B 4.45B 4.35B 187B
Net Debt 8.71B 7.54B 7.04B 6.46B 12.15B 829B 12.34B 82.59B 32.42B 416B 32.73B 32.01B 1,374B 7.98B 6.9B 6.44B 5.91B 11.12B 759B 11.29B 75.6B 29.67B 381B 29.95B 29.3B 1,258B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
07/08/26 $132.19 -0.13% 779,357
06/08/26 $132.36 +1.30% 1,125,931
05/08/26 $130.66 +1.42% 1,118,928
04/08/26 $128.83 +3.64% 1,133,249
03/08/26 $124.30 +1.01% 709,405
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
93.11USD
Average target price
96.79USD
Spread / Average Target
+3.96%

Quarterly revenue - Rate of surprise